

# id.DRIVE

An open public-private partnership  
for infectious diseases studies on vaccines,  
burden of disease and therapeutics  
in Europe and beyond



## The Partnership

### Background

id.DRIVE is a **public-private partnership** fostering research on vaccines and infectious diseases. id.DRIVE (launched in 2024) is the successor of COVIDRIVE (launched in 2021). id.DRIVE is **open** to new Partners and Study Contributors.

### Scope of studies

Observational and low-interventional studies on vaccines, related preventive measures, therapeutic and diagnostics for infectious diseases:

- Burden of disease & health care resource utilisation
- Effectiveness studies
- Impact of prevention programs
- Safety studies

### Partners

Current Non-industry

**Fisabio Foundation**  
Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (SPAIN)

**P95**  
CRO in Vaccines and Infectious diseases (BELGIUM)

Industry

**Pfizer** (USA) **Novavax** (USA) **AstraZeneca** (UK)

Former Non-industry


**THL**

Industry

**CureVac** **GSK** **Janssen** **Moderna** **Valneva** **Sanofi**

### Study Contributors


- From April 2021 to March 2025, **over 20,400** patients have been recruited from a large network of hospitals in **Europe**.
- Hospitals in **other regions** of the world (e.g. Canada) will be opened for recruitment.



## The Studies

id.DRIVE has activated **3 studies** with prospective full-year data collection in Severe Acute Respiratory (**SARI**) patients. Data collection costs are shared between the industry partners. P95 is the Study Sponsor on behalf of the id.DRIVE partnership.

- Study period
- Final internal report
- Final regulatory report
- Scientific manuscript



VE = vaccine effectiveness

### Data Collection

- Population**
- Adults (18y+);
  - ≥1 overnight hospital stay
  - Informed Consent
- + Severe Acute Respiratory Infection (**SARI**)

- Laboratory testing**
- Swab/respiratory sample
  - Viral respiratory PCR multiplex panel:
    - SARS-CoV2
    - Influenza A (H1, H3) and B
    - RSV A and B
    - hMPV
    - Rhinovirus
    - Enterovirus
    - PIV 1-4
    - Adenovirus
    - Bocavirus 1-3
    - Coronavirus 229E, NL63, OC43, HKU1

- Variables**
- Demographics and risk factors
  - Hospital outcomes (ICU, respiratory support, in-hospital death)
  - Laboratory and vaccine data

id.DRIVE is a successful open public-private partnership supporting a **sustainable network of hospitals** for research on infectious diseases, vaccines and therapeutics.

### Acknowledgments

The authors thank the members of the id.DRIVE Independent Scientific Committee for their valuable scientific advice.

The authors thank Valencia Hospital Network for the Study of Infectious Diseases (VAHNSI), Le Centre Hospitalier Universitaire St Pierre, Universitair Ziekenhuis Antwerpen, Grand Hôpital de Charleroi, Centro Interuniversitario per la Ricerca sull'Influenza e le altre Infezioni Trasmissibili (CIRI-IT), Luigi Sacco Hospital, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron, Hospital clínico Universitario de Santiago, Hospital La Paz, hOSPITAL clinic de Barcelona, Klinik Favoriten, Universitätsklinikum Ulm, Universitätsklinikum Frankfurt, and Universitätsklinikum Freiburg for their data collection.

Brenda Marquina Sánchez (FISABIO), Juliette Moyersoen and Ana Goios (P95) supported the creation of this poster.

### Conflict of Interest Statement

The partnership received funds from AstraZeneca, Bavarian Nordic, CureVac, GlaxoSmithKline (GSK), Janssen, Moderna, Novavax, Pfizer, Sanofi, and Valneva, and leveraged public health capacity from the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) and the Finnish Institute for Health and Welfare (THL), and existing infrastructure at P95.

### Selected publications

AstraZeneca

Pfizer

Janssen



iddrive.eu